Repligen Cp Up 21.31% To $138.50 After Earnings Beat

Tuesday, October 31, 2023 - Repligen Cp (RGEN) reported upside earnings and revenues today.

Repligen Cp's earnings came in at an EPS of $0.23 per share, 35.00% higher than estimates for an EPS of $0.17 per share. The firm's earnings are down 70% since reporting $0.77 per share in the same period a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Revenues were upbeat at $141.2 million. That represents a 29.66% decrease in revenues from the year-ago report and is 0.39% higher than consensus estimates set at $140.6 million.

The stock is up 21.31% to $138.50 after the report.

Repligen Cp's profit margins took a hit as earnings fell at a faster pace than revenues.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Repligen Cp a Bearish Sentiment Rank from InvestorsObserver.

Repligen Cp has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 17, putting Repligen Cp in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $110.45 on October 30, 2023 and set a 52-week high on November 15, 2022 at $212.17.

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.